TG Therapeutics, Inc. (TGTX) analyst actions
Rating and price-target actions on TGTX in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the TGTX overview →
2 measured TGTX analyst action events.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| TG Therapeutics Announces Initiation of Phase 2 Trial Evaluating BRIUMVI in Patients with Treatment-Resistant Schizophrenia | Press release | +4.43% | +4.48% | |
| TG Therapeutics Announces Positive Topline Phase 1 Data for Subcutaneous BRIUMVI in Patients with Myasthenia Gravis and Initiation of Potential Registration Directed Randomized Phase 2 Trial | Press release | +0.28% | +2.10% |
Keep exploring
More TGTX: earnings → · SEC filings → · TGTX overview →
Other Healthcare names and their analyst actions
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| OWC PHARMS RESEARCH CORP (OWCP) | 220 | +0.09% | 52% |
| PROVECTUS BIOPHARMS (PVCT) | 220 | +0.01% | 50% |
| Lipocine Inc. (LPCN) | 219 | +0.34% | 52% |
| Mettler-Toledo International, Inc. (MTD) | 219 | -0.10% | 39% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its analyst actions — that is what the link opens.